Blood biomarkers (BBMs) for Alzheimer’s disease (AD) may revolutionize the diagnosis of AD in the future, but they are not yet ready for widespread use in the clinic, according to a global expert workgroup.
The workgroup’s recommendations were published online and presented at AAIC 2022. The cover the use of biomarkers such as plasma measures of Aβ42/Aβ40, phosphorylated tau, and neurofilament light chain (NfL).